“Among persons with impaired fasting glucose levels or impaired glucose tolerance, the use of ramipril [Altace] for three years does not significantly reduce the incidence of diabetes or death.”
Altace, an ACE inhibitor, was studied in a double-blind randomized clinical trial.
“We randomly assigned 5,269 participants without cardiovascular disease but with impaired fasting glucose levels or impaired glucose tolerance to receive Altace (up to 15 mg per day) or placebo (and Avandia or placebo) and followed them for a median of three years,” write the researchers.
At the end of the study, the average fasting plasma glucose level was not significantly lower in the Altace group (102.7 mg/dl) than in the placebo group (103.4 mg/dl), though plasma glucose levels two hours after a meal were lower in the Altace group (135.1 mg/dl vs. 140.5 mg/dl respectively).
* * *
Source: The New England Journal of Medicine, October 12, 2006